Sirtuin Proteins and Memory: A Promising Target in Alzheimer’s Disease Therapy? DOI Open Access
Francesca Fernandez, Lyn R. Griffiths, Heidi G. Sutherland

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(23), P. 4088 - 4088

Published: Nov. 27, 2024

Sirtuins (SIRTs), nicotine adenine dinucleotide (+)-dependent histone deacetylases, have emerged as critical regulators in many signalling pathways involved a wide range of biological processes. Currently, seven mammalian SIRTs been characterized and are found across number cellular compartments. There has considerable interest the role brain due to their plethora metabolic- age-related diseases, including involvement learning memory function physiological pathophysiological conditions. Although cognitive declines over course healthy ageing, neurological disorders Alzheimer's disease (AD) can be associated with progressive impairments. This review aimed report integrate recent advances understanding dysfunction context AD. We also reviewed use selective and/or natural SIRT activators potential therapeutic agents adjuvants for

Language: Английский

ROS-related nanoparticles for the management of Alzheimer’s disease: Wielding the double-edged sword DOI

Yibin Yu,

Qi Zhang, Yihao Guo

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161784 - 161784

Published: March 1, 2025

Language: Английский

Citations

0
Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease DOI Creative Commons
Xiaoming Qi, Damir Nizamutdinov, Sheng‐Han Yi

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2636 - 2636

Published: Nov. 19, 2024

Alzheimer's Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of beta1-40 and 1-42, intracellular neurofibrillary tangles (NFTs). For decades, neuroscience research has heavily focused on seeking to understand the primary mechanism searching for pharmacological approaches treatment dementia. Three monoclonal antibodies that act against beta-aducanumab, lecanemab, donanemab-have been approved Food Drug Administration (FDA) mild cognitive impairment AD, addition medications symptom management such as acetylcholinesterase inhibitors N-methyl-D-aspartate (NMDA) antagonist. Further trials should focus combination therapies targeting tau pathology.

Language: Английский

Citations

0
Sirtuin Proteins and Memory: A Promising Target in Alzheimer’s Disease Therapy? DOI Open Access
Francesca Fernandez, Lyn R. Griffiths, Heidi G. Sutherland

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(23), P. 4088 - 4088

Published: Nov. 27, 2024

Sirtuins (SIRTs), nicotine adenine dinucleotide (+)-dependent histone deacetylases, have emerged as critical regulators in many signalling pathways involved a wide range of biological processes. Currently, seven mammalian SIRTs been characterized and are found across number cellular compartments. There has considerable interest the role brain due to their plethora metabolic- age-related diseases, including involvement learning memory function physiological pathophysiological conditions. Although cognitive declines over course healthy ageing, neurological disorders Alzheimer's disease (AD) can be associated with progressive impairments. This review aimed report integrate recent advances understanding dysfunction context AD. We also reviewed use selective and/or natural SIRT activators potential therapeutic agents adjuvants for

Language: Английский

Citations

0